Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
FDA grants Orphan Drug Designation
FDA grants Orphan Drug Designation status to Zai Lab’s lung cancer treatment
India eyes Asean to boost pharma exports
India eyes Asean to boost pharma exports
Biogen’s
Biogen’s higher dose Spinraza under review by US and EU regulators
Ziapin2
Ziapin2 effectively restores retinal function in preclinical models of retinitis pigmentosa and macular degeneration
Bluejay Therapeutics Receives
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
Dyne
Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate
Withdraws U.S. from World Health Organization
President Trump Withdraws U.S. from World Health Organization
Arrowhead’s
Arrowhead’s plozasiran set for FDA review as Tryngolza challenge looms
Moderna from HHS for mRNA
$590m to Moderna from HHS for mRNA ‘flu vax development
AstraZeneca
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
FDA issues warning
FDA issues warning against using epinephrine nasal solutions from BPI Labs, Endo USA
CDE grants Breakthrough
CDE grants Breakthrough Therapy Designation to Innovent’s IBI343 for pancreatic cancer
47
48
49
50
51
52
53
54
